Objective-Estradiol (E2) mediates numerous beneficial effects assigned to estrogens, but whereas mechanisms have been described at the endothelial level, direct effects on vascular smooth muscle cells (VSMC) are poorly documented. As evidence accumulates regarding the role of RhoA in vascular pathophysiology and the benefit of RhoA-Rho associated protein kinase (Rock) pathway inhibition, we analyzed if E2 could inhibit it in VSMC. Methods and Results-We show that in VSMC, E2 inhibits the RhoA-Rock pathway in a time-and concentrationdependent manner. The inhibition of RhoA-Rock pathway results from E2-induced phosphorylation of the Ser188 of RhoA. Using pharmacological, transfection, and in vitro phosphorylation experiments, we demonstrate that AMP-activated protein kinase subunit alpha 1 (AMPK␣1) is activated by estrogen receptor stimulation and catalyzes RhoA phosphorylation induced by E2. Ex vivo, ovariectomy leads to an increase in the amplitude of phenylephrine-or serotonine-induced contractions of aortic rings in wild-type mice but not in AMPK␣1-knock-out mice or E2-supplemented animals. These functional effects were correlated with a reduced level of RhoA phosphorylation in the aorta of ovariectomized female, male, and AMPK␣1 knock-out mice. Conclusion-Our work thus defines AMPK␣1 as (1) a new kinase for RhoA and (2) Key Words: cell physiology Ⅲ g proteins Ⅲ signal transduction Ⅲ vasoconstriction Ⅲ estrogen I n the vasculature, RhoA and its downstream effector Rho associated protein kinase (Rock) have been shown to regulate processes such as vascular smooth muscle cell (VSMC) contraction, proliferation and differentiations, endothelial permeability, platelet activation, and leukocyte migration. 1 Accordingly, basal RhoA activity is required for homeostatic functions in physiological conditions, but its sustained overactivation has pathological consequences in the vascular system, particularly in VSMC. Activation of RhoAdependent pathways is involved in excessive contraction, and thereby increases blood pressure, but also in excessive cell growth and migration that participate in pathological cardiovascular remodeling. 2 Several regulatory proteins thus cooperate to provide a tight control of RhoA activity including RhoA exchange factors and RhoA GTPase activating proteins that control the GDP/GTP cycle, and Rho guanine dissociation inhibitor (RhoGDI) that sequesters RhoA in the cytosol. 3 In addition to this regulation and independently of GDP-GTP cycling, recent reports have proposed that phosphorylation/ dephosphorylation cycle also controls Rho protein activity. cAMP-and cyclic GMP-dependent protein kinases (PKA and PKG) phosphorylate RhoA on Ser188. 4,5 Both in vitro and in vivo experiments indicated that Ser188 phosphorylation of RhoA induces increased association to GDI leading to cytosolic accumulation of RhoA, 6 inhibition of RhoA-mediated target activation and functions 7 and vasodilation. 5 Recently, we showed that stimulation of angiotensin II type 2 receptor (AT 2 R) in VSMC induces RhoA phosphorylation by the Ste20-related kinase SLK, which contributes to the vasodilatory effect of AT 2 R. 8 In fact, functional consequences of RhoA phosphorylation mimics RhoA-Rock inhibition that reverses or delays vascular pathology development. 9 Conversely, vascular remodeling observed in pathological conditions in particular diabetes is associated with a loss of RhoA phosphorylation. 10 RhoA phosphorylation thus appears as a simple physiological mechanism that could be used to control the dynamics of RhoA protein actions and to permit specific limitation or termination of RhoA protein signals.
I n the vasculature, RhoA and its downstream effector Rho associated protein kinase (Rock) have been shown to regulate processes such as vascular smooth muscle cell (VSMC) contraction, proliferation and differentiations, endothelial permeability, platelet activation, and leukocyte migration. 1 Accordingly, basal RhoA activity is required for homeostatic functions in physiological conditions, but its sustained overactivation has pathological consequences in the vascular system, particularly in VSMC. Activation of RhoAdependent pathways is involved in excessive contraction, and thereby increases blood pressure, but also in excessive cell growth and migration that participate in pathological cardiovascular remodeling. 2 Several regulatory proteins thus cooperate to provide a tight control of RhoA activity including RhoA exchange factors and RhoA GTPase activating proteins that control the GDP/GTP cycle, and Rho guanine dissociation inhibitor (RhoGDI) that sequesters RhoA in the cytosol. 3 In addition to this regulation and independently of GDP-GTP cycling, recent reports have proposed that phosphorylation/ dephosphorylation cycle also controls Rho protein activity. cAMP-and cyclic GMP-dependent protein kinases (PKA and PKG) phosphorylate RhoA on Ser188. 4, 5 Both in vitro and in vivo experiments indicated that Ser188 phosphorylation of RhoA induces increased association to GDI leading to cytosolic accumulation of RhoA, 6 inhibition of RhoA-mediated target activation and functions 7 and vasodilation. 5 Recently, we showed that stimulation of angiotensin II type 2 receptor (AT 2 R) in VSMC induces RhoA phosphorylation by the Ste20-related kinase SLK, which contributes to the vasodilatory effect of AT 2 R. 8 In fact, functional consequences of RhoA phosphorylation mimics RhoA-Rock inhibition that reverses or delays vascular pathology development. 9 Conversely, vascular remodeling observed in pathological conditions in particular diabetes is associated with a loss of RhoA phosphorylation. 10 RhoA phosphorylation thus appears as a simple physiological mechanism that could be used to control the dynamics of RhoA protein actions and to permit specific limitation or termination of RhoA protein signals.
The incidence of cardiovascular diseases is lower among premenopausal women than in age-matched men or in postmenopausal women. 11, 12 Although the specific mechanisms by which female gender is vasoprotective are not fully elucidated, the decreased protective effect against cardiovascular diseases, such as hypertension, in postmenopausal women is thought to be because of endogenous ovarian estrogen depletion. Estradiol (E2) predominant estrogen decreases arterial pressure by modulating autonomic function of the cardiovascular system 13 and through direct effects on blood vessels, 14 which have been essentially ascribed to an endothelial protective action. 11, 12, 15 Genomic and nongenomic mechanisms have been described at the endothelial level to explain the protective effect of E2. 16 -18 However, estradiol-mediated vascular protection could also involve direct effect on vascular smooth muscle. In this context, inhibition of RhoA/Rho kinase by RhoA phosphorylation may constitute a plausible explanation for the effect ascribed to estradiol. Therefore, in the present study, we directly analyzed the effect of E2 on serine phosphorylation of RhoA both in vitro in VSMCs and in/ex vivo in artery samples. We describe a new signaling cascade activated following E2 stimulation that leads to AMP-activated protein kinase (AMPK)␣1 activation, RhoA phoshorylation, and RhoA/Rho kinase signaling inhibition. We thus identify AMPK␣1 as a novel kinase for RhoA that may contribute to the vasoprotective effects of estrogen by limiting the contraction.
Methods
VSMC were obtained from explants of rat aorta and used at passage 2 to 4 for this study. Cells were placed in complete fresh Dulbecco's modified minimal essential medium without phenol red 24 hours before the pharmacological treatments. Inhibitors were applied 45 minutes before other treatments. Mouse embryonic fibroblasts (MEFs) from wild-type and AMPK␣1-deficient mice (described elsewhere 19, 20 ) were cultured and treated as VSMC. Western Blot analysis was performed as previously described. 6 Direct AMPK activity was measured using human recombinant AMPK (Merck) and ␥[32P] incorporated into SAMS peptide substrate (HMRSAMSGLHLVKRR) or recombinant wildtype (WT) or phosphoresistant (S188A) RhoA. Rock-1 or Rock-2 were immunoprecipitated from lysates of VSMC or MEF treated or not with E2 for 6 hours and used for kinase assay on S6 substrate. After incubation for 30 minutes at 30°C, assays were terminated by phosphoric acid and revealed as phospho-cellulose binding assay. 21 Wild-type or AMPK␣1-deficient mice have been described elsewhere. 22 After bilateral ovariectomy under isoflurane anesthesia, WT or AMPK␣1-deficient female mice (10 to 20 wk old) were treated daily with E2 (subcutaneous, 0.1 mg/kg/d; OXVϩE2) or placebo and buprenorphine and carprofen analgesia for the following procedure. After 7 to 10 days, they were euthanized by cervical dislocation. Their spleens were weighted to control the mice genotype [WT spleen 103Ϯ45 mg versus alpha 1 knock-out (KO) spleen 252Ϯ60 mg] and their aorta used for Western blot or tension analysis. Isometric tension of arterial rings of thoracic aorta was measured as previously described. 23 For details, please refer to the Supplemental Methods, available online at http://atvb.ahajournals.org.
Results

E2 Inhibits RhoA-Rock Pathway Through RhoA Phosphorylation in VSMC
To determine if estradiol can induce RhoA-Rock pathway inhibition and RhoA phosphorylation in smooth muscle, we analyzed the effect of E2 on VSMC. We measured the phosphorylation of the Rock target MYPT in VSMC stimulated either with 10 Ϫ9 mol/L E2 for different times, or with different E2 concentrations for 1 hour. E2 induced a time-and dose-dependent dephosphorylation of MYPT ( Figure 1A and 1C) and, in parallel, a time-and dose-dependent phosphorylation of RhoA ( Figure 1B and 1D) . Analysis of the RhoARock pathway in VSMC expressing WT (WT-RhoA) or phosphoresistant (S188A-RhoA) mutant showed that S188A-RhoA expression prevented both E2-induced RhoA phosphorylation (1.26Ϯ0.23 after 6 hour versus 2.98Ϯ0.32 after 6 hours in WT-RhoA expressing cells) and E2-induced MYPT dephosphorylation (1.07Ϯ0.28 after 6 hours versus 0.18Ϯ0.22 after 6 hours in WT-RhoA expressing cells) ( Figure 1E ). Measurement of kinase activity of Rocks demonstrated that Rock1, but not Rock2, activity was significantly reduced in VSMC treated with E2 ( Figure 1F ). These results demonstrate that through direct action on VSMC, E2, at doses close to physiological concentrations (1 nmol/L), induced RhoA phosphorylation on Ser188 that is responsible for the RhoA-Rock pathway inhibition.
E2 Induces RhoA Phosphorylation and Rock1 Inhibition Through AMPK
We then adopted a pharmacological approach to identify the kinase responsible for RhoA phosphorylation and RhoARock pathway inhibition induced by E2 in VSMC. PKA is known to phosphorylate RhoA on Ser188 and to be activated by E2. 24 Pretreatment with the PKA inhibitor H89 affected neither RhoA phosphorylation nor RhoA-Rock pathway inhibition induced by E2 (Figure 2A ) demonstrating no major involvement of PKA in this signaling. The AMP-activated protein kinase (AMPK) is another candidate serine-threonine kinase described to be activated by E2 in myotubes. 25 The AMPK inhibitor compound C decreased the basal level of RhoA phosphorylation but also prevented the E2-induced RhoA phosphorylation ( Figure 2A ). This effect was associated with an increase in the basal MYPT phosphorylation and an inhibition of the dephosphorylation induced by E2 ( Figure  2A ). Consistently, analysis of the phosphorylation of AMPK itself and of its AMPK substrate acetyl-CoA carboxylase (ACC) showed that E2 activated AMPK in VSMC ( Figure  2A and 2B). These results were confirmed by analysis in mouse embryonic fibroblasts (MEF) from AMPK ␣1-KO or -WT mice. E2-induced RhoA phosphorylation was almost lost in KO animals ( Figure 2C ). In the same manner, the decrease in the phosphorylation of 2 Thr residus of MYPT phosphorylated by Rock (Thr 697 and 855 in rattus sequence, and Thr 696 and 853 in human sequences) induced by E2 in VSMC and in WT MEFs is not observed in MEF from AMPK ␣1-KO mice (Figure 2A -C). Rock1 activity was also decreased in WT MEF treated with E2, whereas no significant changes were observed in AMPK ␣1-KO MEF ( Figure  2D ). These results demonstrate that E2 phosphorylates RhoA and inhibits the RhoA-Rock pathway through AMPK activation in VSMC. This also shows that the AMPK is basally activated in VSMC.
E2 Induces RhoA Phosphorylation Through Estrogen Receptor
To analyze if E2 induces RhoA phosphorylation and RhoARock pathway inhibition through estrogen receptor (ER) in VSMC, we pretreated the cells with the nonselective ER antagonist ICI182780. ICI182780 pretreatment prevented phosphorylation of RhoA and ACC, and dephosphorylation of MYPT induced by E2 (Figure 2A ). These results demonstrated that AMPK-induced RhoA phosphorylation and RhoA-Rock pathway inhibition are induced by binding of E2 to ER in VSMC.
AMPK Directly Phosphorylates RhoA on Ser188
To assess the possibility that AMPK directly phosphorylates RhoA on its serine residue 188, we first analyzed the affected sequence. Alignment of the C-terminal region of RhoA sequences of different species to the consensus AMPK phosphorylation sequence showed that the K located 3 amino-acid before and the L located 5 amino-acid after the Ser188 corresponded to the consensus sequence ( Figure 3A ). Bioinformatic analysis (http://ppsp.biocuckoo.org/index.php) revealed that AMPK could phosphorylate RhoA on Ser188 with a probability comparable to that obtained for PKG (threshold 3.3 and 3.1; risk 3.5 and 3.46 for AMPK and PKG, respectively) known to phosphorylate RhoA. 5 To confirm this bioinformatic prediction, we performed in vitro kinase assays using recombinant AMPK. WT-RhoA was phosphorylated by the AMPK to the same extent that the SAMS positive control peptide. We estimated that at least 70% to 80% of WT-RhoA protein was phosphorylated by AMPK in vitro. In contrast, the S188A-RhoA mutant lacking the phosphorylation site did not show any phosphate incorporation, as did the RhoGDI (GDI) that is not an AMPK substrate and was used as a negative control ( Figure 3B ). All together, these results describe for the first time that AMPK directly phosphorylates RhoA on Ser188.
RhoA Phosphorylation Is Reduced in Arteries of Male or AMPK␣1 KO Female Mice
To analyze if RhoA phosphorylation induced by E2 through AMPK␣1 could participate in gender differences at the level of the vascular system, we compared the activation of this pathway in aorta from female or male, WT, and AMPK␣1-KO mice (Figure 4) . The level of phosphorylated RhoA, phosphorylated AMPK and phosphorylated ACC was significantly lower in WT males than in WT females, suggesting a reduced activity of AMPK␣1 pathway in males. Deletion of AMPK␣1 induced a significant decrease in RhoA, AMPK and ACC phosphorylation in female that reached levels similar to that observed in both WT and AMPK␣1-KO male (Figure 4 ). This shows that AMPK␣1 is responsible for the higher RhoA phosphorylation in arteries of female mice. All together these results demonstrate that AMPK␣1-RhoA pathway is constitutively more activated in female that in male mice and could be responsible for vasoprotective effects of estrogens.
AMPK Activation Limits Vasoconstriction Independently of NO
To evaluate the effect of AMPK on VSMC function, we first have used a pharmacological approach consisting in analyzing the effect of AMPK activators, AICAR and metformin on vasoreactivity. To eliminate the already described effect of AMPK activation on nitric oxide (NO) production, experiments were performed in the continuous presence of the NO synthase inhibitor (L-NNA 2.10 Ϫ4 mol/L). L-NNA inhibition was controlled by the absence of carbachol (10 Ϫ5 mol/L)-induced vasorelaxation on mice aortic rings precontracted with phenylephrine (data not shown). When used as pretreatment, AICAR or metformin significantly reduced the maximal contraction induced by phenylephrine ( Figure 5A ), suggesting that AMPK activation limits agonist-induced vascular smooth muscle contraction. To identify a possible mechanism responsible for AMPK activation effects, we next analyzed RhoA phosphorylation and RhoA-Rock pathway activity on VSMC treated with AICAR or metformin. Both induced the phosphorylation of RhoA in concomitance with dephosphorylation of MYPT (Supplemental Figure I) . Similar effects were obtained by expressing constitutively active mutant of AMPK (CA) in VSMC (Supplemental file). In contrast, expression of a dominant negative form of AMPK (DN) increased MYPT phosphorylation and decreased the RhoA phosphorylation (Supplemental Figure I) . These results show that independently of the tested activator, AMPK activation induces RhoA phosphorylation and RhoA-Rock pathway inhibition.
Estradiol Induces RhoA Phosphorylation and Limits Vasoconstriction Through AMPK␣1
To analyze the vascular consequences of the newly described E2-AMPK-RhoA pathway in arteries, we measured the vasoreactivity of aorta rings from WT or AMPK␣1-KO female mice, ovariectomized or not, and daily supplemented with E2 or not. As previously described, all experiments were performed in presence of L-NNA (2.10 Ϫ4 mol/L). The amplitude of the contraction induced by 60 mmol/L of KCl was similar in WT and AMPK␣1-KO aortic rings ( Figure 5B ). Ovariectomy significantly increased the contraction of WT aorta in response to phenylephrine. This increase was prevented by the daily supplementation with E2 ( Figure 5C ). In contrast ovariectomy or E2 supplementation had no effect on AMPK␣1-KO aortic ring responses to phenylephrine, that, in control condition were already higher than those obtained in WT mice and comparable to the responses of ovariectomized WT aortic rings ( Figure 5C ). The same results were observed for the contractile response to serotonin (5HT) ( Figure 5D ). Measurement of RhoA phosphorylation in aorta form WT or AMPK␣1-KO mice showed that ovariectomy decreased RhoA phosphorylation and that E2 supplementation prevented this effect in aortas from WT mice. No change was observed in aorta of AMPK␣1-KO mice in which RhoA phosphorylation remained low in the 3 conditions ( Figure 6 ). AMPK phosphorylation was also greatly reduced in aortas from WT ovariectomized mice and this effect was reversed by E2 supplementation (Figure 6 ). On the contrary, MYPT phosphorylation was increased in ovariectomized WT mice and in AMPK␣1-KO mice. Ovariectomy or E2 supplementation did not induce any effect on MYPT phosphorylation in AMPK␣1-KO mice ( Figure 6 ). All together, these results suggest that RhoA phosphorylation and RhoA-Rock pathway To analyze in vivo if the differences in the level of RhoA phosphorylation observed in arteries of WT females and males and in AMPK␣1 KO mice were associated with change in blood pressure regulation, we have measured systolic blood pressure in female and male AMPK␣1-KO mice (Supplemental Figure II) . Under basal condition, systolic blood pressure in male and female AMPK␣1-KO mice was similar to that of WT mice. Under these conditions, the level of RhoA/Rho kinase activation and P-MYPT phosphorylation is low. It is therefore logical that the inhibitory action of AMPK␣1-mediated RhoA phosphorylation on this pathway had no effect on basal blood pressure. This is in agreement with the absence of effect of Rho kinase inhibitors on blood pressure in normotensive animals. 26 L-NAME treatment revealed differences between the AMPK␣1-KO and WT mice. In WT mice, L-NAME treatment induced hypertension earlier and stronger in male than in female (Supplemental Figure II) . After 2 days of L-NAME treatment, maximal increase in blood pressure was already observed in males (around 35 mm Hg) whereas there was no change in blood pressure in females, and the maximal rise observed after 14 days of L-NAME in females was smaller than in males (around 20 mm Hg). In AMPK␣1-KO mice, there was no difference in males and females: L-NAME induced a rise (around 35 mm Hg) in blood pressure that was already maximal after 2 days of treatment. These data thus suggest that AMPK␣1 partially protects females from L-NAME inducedhypertension. All together, our data support the idea that estrogen-dependent, AMPK␣1-mediated phosphorylation of RhoA observed in arteries of female mice participates to the vasoprotective effects of estrogens.
Discussion
Our work identifies AMPK␣1 as a new kinase that phosphorylates Ser188 of RhoA and establishes a novel signaling cascade induced by estradiol. In VSMC, ER stimulation by E2 activates AMPK that phosphorylates RhoA thereby reducing Rho-Rock signaling pathway activity and limiting vasoconstriction. Our results also demonstrate that AMPK␣1-RhoA pathway is constitutively active in female mice and could thus participate to the vasoprotective effect of estrogens.
AMPK is an ubiquitous heterotrimeric serine/threonine protein kinase activated by pathological stimuli, such as oxidative damage, osmotic shock, hypoxia, and glucose deprivation, as well as by physiological stimuli such as exercise and muscle contraction, and by hormones including leptin and adiponectin. 27 In general, AMPK is activated in response to decreased cellular energy charge (increased in AMP/ATP ratio) and regulates carbohydrate and lipid metabolism. 28 -30 Although there is a robust correlation between the activity of the AMPK and the metabolic control in skeletal muscle or heart, the role of the AMPK activity in other organs is less studied. In the vasculature, AMPK can be regulated by hypoxia as well as fluid shear stress and has been implicated in the regulation of fatty acid oxidation and nitric oxide production as well as inflammation in endothelial cells. 31 More recently, AMPK has been shown to preserve endothe- lial function by limiting Nox2 expression. 22 Activation of AMPK by AICAR has been shown to inhibit VSMC proliferation and neointimal formation after vascular injury, 32, 33 to induce vasorelaxation independently of the endothelium 34, 35 and to reduce blood pressure of diabetic rats. 35 Using AMPK KO mice, our work demonstrates that AMPK␣1 activity in VSMC limits vascular contraction. This constitutes other evidence indicating that AMPK activation may help to prevent the vascular complications associated with the metabolic syndrome. 31 The identification of the Ser188 of RhoA as a target for AMPK-mediated phosphorylation provides a molecular mechanism supporting the inhibitory action of AMPK on smooth muscle contraction. Phosphorylation of the 20kDa-myosin light chain (MLC) is the key event of the regulation of vascular smooth muscle contraction. MLC is phosphorylated by the Ca 2ϩ -calmodulin activated MLC kinase (MLCK) and dephosphorylated by the Ca 2ϩ -independent MLC phosphatase (MLCP). MLCP is phosphorylated and inhibited by Rock, which leads to increased MLC phosphorylation and tension at a constant Ca 2ϩ concentration. Goirand et al observed that activation AMPK␣1, but not AMPK␣2, induced aortic relaxation in mice in an endothelium-and eNOS-independent manner. 34 By inhibiting RhoA-Rock pathway activity and by consequence, the phosphorylation of MLCP, AMPK-mediated RhoA phosphorylation in VSMC directly decreases the level of MLCP and, therefore, the level of contraction. It has been previously suggested that AMPK attenuates smooth muscle contraction by phosphorylating and inactivating MLCK. 36 Our results do not support a major involvement of this pathway as the amplitude of the contraction induced by KCl that mainly depends on Ca 2ϩ -mediated MLCK activation was not different in arteries of AMPK␣1 KO mice from that obtained in arteries of WT mice.
Phosphorylation of RhoA and inhibition of RhoA-Rock signaling thus appears as an important mediator of the limiting action of AMPK on VSMC cell contraction. This mechanism of action of AMPK does not seem to be limited to systemic VSMCs as AMPK activator, AICAR, and metformin have been shown to inhibit Rock activity in osteoblastic MC3T3 cells 37 and pulmonary artery smooth muscle cells. 38 More generally, as AMPK␣1 and RhoA are ubiquitously expressed, phosphorylated RhoA might be a common downstream effector of AMPK in numerous cell types including cardiac and skeletal muscle cells that contributes to the metabolic effects of AMPK and pharmacological effects of AMPK activators such as metformin. The modulation of the vasoreactivity resulting from the AMPK-RhoA pathway and the proproliferative and -migrative effects of phosphorylated RhoA 7 suggest that the AMPK-RhoA pathway activation may help to counteract the healing defect observed during diabetic pathology. 39, 40 By demonstrating that AMPK is an effector of E2, we show that AMPK-RhoA pathway participate to gender differences in vascular function. Women develop coronary heart disease on average 10 years later than men. This has been attributed, at least in part, to the protective effects of female sex hormones, particularly estrogens, before menopause. 41, 42 As predominant estrogen, E2 mediates numerous beneficial effects assigned to estrogens, such as blood pressure lowering, 12, 14 angiogenesis promotion, or early atheroma prevention. 15 E2 actions are mediated by genomic and nongenomic mechanisms. The classical genomic mechanism of E2 action involves activation of its nuclear receptor (ER-␣ or -␤), receptor dimerization, and subsequent binding to ER response elements located in the promoter of target genes. More recently, E2 has been shown to have rapid, nongenomic biological effects, believed to be mediated through membrane-bound subpopulation of ER-␣ and ER-␤ and/or the newly described G protein-coupled receptor 30. 43, 44 The results obtained using the ICI182780 inhibitor, argue against a role for the G protein-coupled receptor 30 but for the involvement of ER-␣ or ER-␤ in the vasoprotective effects of E2 observed. Concerning the vasculature, ER-␣ and ER-␤ are present both on endothelial and smooth muscle cells, 11 but most of these studies concern the endothelium, and a few consider a possible smooth muscle implication. Indeed, endothelial ER stimulation induces vascular wall dilation 16, 18 mainly through an increased nitric oxide production 45 due to rapid eNOS activation 18, 46, 47 or induction of eNOS expression. 17 E2 has also been shown to stimulate endothelial cell survival and formation of primary capillary tube. 48 At the media level, E2 regulates smooth muscle cell proliferation, 12 differentiation, apoptosis, 49 and even contraction. 17 The mechanisms underlying these effects are poorly described, implicating ERK/MAPKs and p38/SAPKs2 balance or PI3K-Akt and Src signaling, and cannot explain all the E2 effects. 47, 49, 50 Recently, although the mechanism involved has not been identified, it has been suggested that inhibition of Rho-Rock pathway in the central nervous system or in the vasculature might participate to the limitation of arterial contraction induced by E2. 51 The observation that E2-induced AMPK-mediated RhoA phosphorylation on Ser188 provides the molecular mechanism of these observed effects. Both in vitro and in vivo experiments indicated that Ser188 phosphorylation of only a fraction of total RhoA efficiently inactivated RhoA signaling through an increased association to GDI, leading to cytosolic sequestration of RhoA, 6 inhibition of RhoA-mediated target activation and functions 7 and vasodilation. 5 In agreement with these reports, here we show that expression of a phosphoresistant form of RhoA blocked MYPT dephosphorylation induced by E2 thus suggesting that E2-induced inhibition of RhoA-Rho kinase signaling resulted from phosphorylation of RhoA on Ser188.
The identification of AMPK activation and RhoA-Rock inhibition can explain E2 effects, and it would be interesting to consider AMPK activation and RhoA phosphorylation as inducers of estrogen vasoprotection, and even as mediators of estrogen signaling in the whole organism.
